Skip to main content

Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn’s disease: results from a multicenter phase I/IIa clinical trial

Abstract

Purpose

The management of perianal fistula in patients with Crohn’s disease is an extremely challenging medical problem as many fistulas do not respond to available treatments. The objectives were to assess the safety and efficacy of a suspension of expanded adipose-derived allogeneic mesenchymal stem cells (eASCs) for the treatment of complex perianal fistula in Crohn’s disease

Methods

An open-label, single-arm clinical trial was conducted at six Spanish hospitals. Twenty-four patients were administered intralesionally with 20 million eASCs in one draining fistula tract. A subsequent administration of 40 million eASCs was performed if fistula closure was incomplete at week 12. Subjects were followed until week 24 after the initial administration.

Results

Treatment-related adverse events did not indicate any clinical safety concerns after 6 months follow-up. The full analysis of efficacy data at week 24 showed 69.2 % of the patients with a reduction in the number of draining fistulas, 56.3 % of the patients achieved complete closure of the treated fistula achieved, and 30 % of the cases presenting complete closure of all existing fistula tracts. Of note, closure was strictly defined as: absence of suppuration through the external orifice and complete re-epithelization, plus absence of collections measured by magnetic resonance image scan (MRI). Furthermore, MRI Score of Severity showed statistically significant differences at week 12 with a marked reduction at week 24.

Conclusions

Locally injected eASCs appear to be a simple, safe, and beneficial therapy for perianal fistula in Crohn’s disease patients. Additional studies are needed to further confirm the efficacy of the eASCs.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. 1.

    Cho JH (2008) The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 8:458–466

    PubMed  Article  CAS  Google Scholar 

  2. 2.

    Hellers G, Bergstrand O, Ewerth S et al (1980) Occurrence and outcome after primary treatment of anal fistula in Crohn’s disease. Gut 21:525–527

    PubMed  Article  CAS  Google Scholar 

  3. 3.

    Schwartz DA, Loftus EV Jr, Tremaine WJ et al (2002) The natural history of fistulizing Crohn’s disease in Olmsted Country, Minnesota. Gastroenterology 122:875–880

    PubMed  Article  Google Scholar 

  4. 4.

    Tozer PJ, Burling D, Gupta A et al (2011) Review article: medical, surgical and radiological management of perianal Crohn’s fistulas. Aliment Pharmacol Ther 33:5–22

    PubMed  Article  CAS  Google Scholar 

  5. 5.

    Singer NG, Caplan AI (2011) Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol 6:457–478

    PubMed  Article  CAS  Google Scholar 

  6. 6.

    Delarosa O, Dalemans W, Lombardo E (2012) Mesenchymal stem cells as therapeutic agents of inflammatory and autoimmune diseases. Curr Opin Biotechnol 23:1–5

    Article  Google Scholar 

  7. 7.

    Di Nicola M, Carlo-Stella C, Magni M et al (2002) Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99:3838–3843

    PubMed  Article  Google Scholar 

  8. 8.

    Krampera M, Glennie S, Dyson J et al (2003) Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101:3722–3729

    PubMed  Article  CAS  Google Scholar 

  9. 9.

    Ghannam S, Pène J, Torcy-Moquet G et al (2010) Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 185:302–312

    PubMed  Article  CAS  Google Scholar 

  10. 10.

    Prigione I, Benvenuto F, Bocca P et al (2009) Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. Stem Cells 27:693–702

    PubMed  Article  CAS  Google Scholar 

  11. 11.

    Corcione A, Benvenuto F, Ferretti E et al (2006) Human mesenchymal stem cells modulate B-cell functions. Blood 107:367–372

    PubMed  Article  CAS  Google Scholar 

  12. 12.

    Raffaghello L, Bianchi G, Bertolotto M et al (2008) Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells 26:151–162

    PubMed  Article  CAS  Google Scholar 

  13. 13.

    Delarosa O, Sánchez-Correa B, Morgado S et al (2012) Human adipose-derived stem cells impair natural killer cell function and exhibit low susceptibility to natural killer-mediated lysis. Stem Cells Dev 21:1333–1343

    PubMed  Article  CAS  Google Scholar 

  14. 14.

    Doorn J, Moll G, Le Blanc K et al (2012) Therapeutic applications of mesenchymal stromal cells: paracrine effects and potential improvements. Tissue Eng Part B Rev 18:101–115

    PubMed  Article  CAS  Google Scholar 

  15. 15.

    DelaRosa O, Lombardo E, Beraza A et al (2009) Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. Tissue Eng Part A 15:2795–2806

    PubMed  Article  CAS  Google Scholar 

  16. 16.

    Krampera M (2011) Mesenchymal stromal cell ‘licensing’: a multistep process. Leukemia 25:1408–1414

    PubMed  Article  CAS  Google Scholar 

  17. 17.

    Le Blanc K, Tammik C, Rosendahl K et al (2003) HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 31:890–896

    PubMed  Article  Google Scholar 

  18. 18.

    Mitchell JB, McIntosh K, Zvonic S et al (2006) Immunophenotype of human adipose-derived cells: temporal changes in stromal-associated and stem cell-associated markers. Stem Cells 24:376–385

    PubMed  Article  Google Scholar 

  19. 19.

    Gonzalez-Rey E, Anderson P, González MA et al (2009) Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 58:929–939

    PubMed  Article  CAS  Google Scholar 

  20. 20.

    González MA, Gonzalez-Rey E, Rico L et al (2009) Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 136:978–989

    PubMed  Article  Google Scholar 

  21. 21.

    Garcia-Olmo D, Garcia-Arranz M, Garcia LG et al (2003) Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn’s disease: a new cell-based therapy. Int J Colorectal Dis 18:451–454

    PubMed  Article  Google Scholar 

  22. 22.

    Garcia-Olmo D, Garcia-Arranz M, Herreros D et al (2005) A phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 48:1416–1423

    PubMed  Article  Google Scholar 

  23. 23.

    Garcia-Olmo D, Herreros D, Pascual I et al (2009) Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum 52:79–86

    PubMed  Article  Google Scholar 

  24. 24.

    Ciccocioppo R, Bernardo ME, Sgarella A et al (2011) Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease. Gut 60:788–798

    PubMed  Article  Google Scholar 

  25. 25.

    Van Assche G, Dignass A, Reinisch W et al (2010) The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: special situations. J Crohn’s Colitis 4:63–101

    Article  Google Scholar 

  26. 26.

    Nikfar S, Mirfazaelian H, Abdollahi M (2010) Efficacy and tolerability of immunoregulators and antibiotics in fistulizing Crohn’s disease: a systematic review and meta-analysis of placebo-controlled trials. Curr Pharm Des 16:3684–3698

    PubMed  Article  CAS  Google Scholar 

  27. 27.

    Pearson DC, May GR, Fick GH et al (1995) Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 123:132–142

    PubMed  CAS  Google Scholar 

  28. 28.

    Sands BE, Anderson FH, Bernstein CN et al (2004) Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 350:876–885

    PubMed  Article  CAS  Google Scholar 

  29. 29.

    Roumeguère P, Bouchard D, Pigot F et al (2011) Combined approach with infliximab, surgery, and methotrexate in severe fistulizing anoperineal Crohn’s disease: results from a prospective study. Inflamm Bowel Dis 17:69–76

    PubMed  Article  Google Scholar 

  30. 30.

    Bourikas LA, Koutroubakis IE (2010) Anti-TNF and fistulizing perianal Crohn’s disease: use in clinical practice. Curr Drug Targets 11:187–197

    PubMed  Article  CAS  Google Scholar 

  31. 31.

    Alessandroni L, Kohn A, Cosintino R et al (2011) Local injection of infliximab in severe fistulating perianal Crohn’s disease: an open uncontrolled study. Tech Coloproctol 15:407–412

    PubMed  Article  CAS  Google Scholar 

  32. 32.

    Wise PE, Schwartz DA (2006) Management of perianal Crohn’s disease. Clin Gastroenterol Hepatol 4:426–430

    PubMed  Article  Google Scholar 

  33. 33.

    Singh B, George BD, Mortensen NJ (2007) Surgical therapy of perianal Crohn’s disease. Dig Liver Dis 39:988–992

    PubMed  Article  CAS  Google Scholar 

  34. 34.

    Whiteford MH, Kilkenny J 3rd, Hyman N et al (2005) Practice parameters for the treatment of perianal abscess and fistula-in-ano (revised). Dis Colon Rectum 48:1337–1342

    PubMed  Article  Google Scholar 

  35. 35.

    Lewis RT, Maron DJ (2010) Anorectal Crohn’s disease. Surg Clin North Am 90:83–97

    PubMed  Article  Google Scholar 

  36. 36.

    Grimaud JC, Munoz-Bongrand N, Siproudhis L et al (2010) Fibrin glue is effective healing perianal fistulas in patients with Crohn’s disease. Gastroenterology 138:2275–2281

    PubMed  Article  CAS  Google Scholar 

  37. 37.

    English K, Mahon BP (2011) Allogeneic mesenchymal stem cells: agents of immune modulation. J Cell Biochem 112:1963–1968

    PubMed  Article  CAS  Google Scholar 

  38. 38.

    Uccelli A, Moretta L, Pistoia V (2006) Immunoregulatory function of mesenchymal stem cells. Eur J Immunol 36:2566–2573

    PubMed  Article  CAS  Google Scholar 

  39. 39.

    Krampera M, Cosmi L, Angeli R et al (2006) Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24:386–398

    PubMed  Article  CAS  Google Scholar 

  40. 40.

    Van Laar JM, Tyndall A (2006) Adult stem cells in the treatment of autoimmune diseases. Rheumatology (Oxford) 45:1187–1193

    Article  Google Scholar 

  41. 41.

    Griffin MD, Ritter T, Mahon BP (2010) Immunological aspects of allogeneic mesenchymal stem cell therapies. Hum Gene Ther 21:1641–1655

    PubMed  Article  CAS  Google Scholar 

  42. 42.

    Rubio D, Garcia S, De la Cueva T et al (2008) Human mesenchymal stem cell transformation is associated with a mesenchymal-epithelial transition. Exp Cell Res 314:691–698

    PubMed  Article  CAS  Google Scholar 

  43. 43.

    Røsland GV, Svendsen A, Torsvik A et al (2009) Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res 69:5331–5339

    PubMed  Article  Google Scholar 

  44. 44.

    Garcia S, Bernad A, Martín MC et al (2010) Pitfalls in spontaneous in vitro transformation of human mesenchymal stem cells. Exp Cell Res 316:1648–1650

    PubMed  Article  CAS  Google Scholar 

  45. 45.

    Torsvik A, Røsland GV, Svendsen A et al (2010) Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track—letter. Cancer Res 70:6393–6396

    PubMed  Article  CAS  Google Scholar 

  46. 46.

    Prockop DJ, Brenner M, Fibbe WE et al (2010) Defining the risks of mesenchymal stromal cell therapy. Cytotherapy 12:576–578

    PubMed  Article  Google Scholar 

  47. 47.

    Malouf AJ, Buchanan GN, Carapeti EA et al (2002) A prospective audit of fistula-in-ano at St. Mark’s hospital. Colorectal Dis 4:13–19

    PubMed  Article  Google Scholar 

  48. 48.

    Jurczak F, Laridon JY, Raffaitin P et al (2004) Biological fibrin used in anal fistulas: 31 patients. Ann Chir 129:286–289

    PubMed  Article  CAS  Google Scholar 

  49. 49.

    Taxonera C, Schwartz DA, Garcia-Olmo D (2009) Emerging treatments for complex perianal fistula in Crohn’s disease. World J Gastroenterol 15:4263–4272

    PubMed  Article  CAS  Google Scholar 

  50. 50.

    Schaffzin DM, Stahl TJ, Smith LE (2003) Perianal mucinous adenocarcinoma: unusual case presentations and review of the literature. Am Surg 69:166–169

    PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank José Luis Bravo and Lydia Dorrego (TiGenix) for their support and contribution during the study conduct.

Competing interests

There are no competing interests

Funding

This study was sponsored by TiGenix (formerly Cellerix).

Author information

Affiliations

Authors

Corresponding author

Correspondence to F. de la Portilla.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

de la Portilla, F., Alba, F., García-Olmo, D. et al. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn’s disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis 28, 313–323 (2013). https://doi.org/10.1007/s00384-012-1581-9

Download citation

Keywords

  • Fistulizing Crohn’s disease
  • Perianal fistula
  • Allogeneic adult stem cells